Clinical Trial Update: Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma [Phase 2]

View source ↗

Summary

Phase 2 trial of marizomib for recurrent ependymoma in various locations was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Ependymoma
• Ependymoma

Drugs mentioned

• Marizomib (marizomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Ependymoma, Ependymoma | Phase 2 | Status: TERMINATED | Results posted: 2021-11-30